|
May 9
|
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
|
|
May 2
|
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results
|
|
Apr 18
|
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
|
|
Mar 15
|
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
|
|
Mar 10
|
Oncternal Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
|
|
Mar 7
|
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
|
|
Feb 29
|
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results
|
|
Jan 2
|
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
|
|
Aug 10
|
Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results
|
|
Apr 27
|
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results
|